TRIM37 is an E3 ubiquitin ligase with multifaceted cellular roles centered on centrosome regulation and epigenetic control. Its primary function involves preventing centrosome overduplication by ubiquitinating positive regulators of centriole reduplication 12. TRIM37 acts as a critical orchestrator of centrosome maturation and function; loss of function causes aberrant centrosomal protein assemblies including Centrobin-PLK4 foci that act as ectopic microtubule-organizing centers, leading to defective chromosome 17 34. TRIM37 mediates monoubiquitination of histone H2AK119, supporting Polycomb-mediated epigenetic repression 5, and stabilizes the peroxisomal protein PEX5 through monoubiquitination 6. Disease relevance is substantial: mutations in TRIM37 cause MULIBREY nanism, an autosomal recessive disorder characterized by growth impairment and tumor predisposition 73. Conversely, TRIM37 amplification in 17q23-amplified breast cancers and neuroblastomas creates synthetic lethality with PLK4 inhibitors, as elevated TRIM37 blocks compensatory acentrosomal spindle assembly and degradation of CEP192 89. Additionally, TRIM37 promotes chemoresistance in ovarian and gastric cancers through NFκB and NRF2 pathway activation 1011. These findings indicate TRIM37 requires optimal expression equilibrium; both loss and gain drive pathological outcomes with therapeutic implications.